Carregant...

Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy

Dronedarone, a new Class III antiarrhythmic agent, has now been approved by the US Food and Drug Administration for use in patients with atrial fibrillation or atrial flutter. Approval came in March 2009 due to the positive results of the ATHENA trial showing significant reductions in all-cause mort...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wolbrette, Deborah, Gonzalez, Mario, Samii, Soraya, Banchs, Javier, Penny-Peterson, Erica, Naccarelli, Gerald
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2922313/
https://ncbi.nlm.nih.gov/pubmed/20730068
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!